摘要
目的探讨阿帕替尼单药治疗晚期三阴性乳腺癌的疗效和不良反应。方法回顾性分析郑州大学第一附属医院收治的22例既往化疗失败或复发转移后接受阿帕替尼单药治疗的晚期三阴性乳腺癌患者的临床资料,观察并记录阿帕替尼治疗晚期三阴性乳腺癌的有效率、疾病控制率、疾病无进展生存时间,寻找影响患者预后的因素。结果22例可评价疗效患者的中位疾病无进展生存时间为107(58.82~123.18)d。治疗后部分缓解3例,疾病稳定12例,疾病进展7例,有效率为13.64%,疾病控制率为68.18%。多因素COX回归分析结果显示:暂未发现ECOG评分(P=0.376)、治疗期间出现的高血压(P=0.338)、手足综合征(P=0.201)是影响晚期三阴性乳腺癌患者疾病无进展生存时间的独立预后因素。阿帕替尼的不良反应大多数为轻中度(1、2级),经处理可以好转或耐受。结论阿帕替尼单药用于晚期三阴性乳腺癌的治疗有一定疗效,不良反应可控,耐受性好,值得进一步研究。
Objective To observe the efficacy and safety of apatinib in the patients with advanced triple-negative breast cancer.Methods The clinical data of all the 22 patients with advanced triple-negative breast cancer who had received apatinib after failure of prior lines of chemotherapy or suffering from the recurrence or metastases were retrospectively analyzed.The objective response rate,disease control rate and disease progression-free survival time were observed,and the independent prognostic factors were analyzed.Results The median disease progression-free survival time of 22 patients was 107(58.82 to 123.18)days.After treatment,3 patients had partial response,12 patients had stable disease,and 7 patients had disease progression,the response rate was 13.64%,and the disease control rate was 68.16%.Multivariate COX analysis results showed that the ECOG score(P=0.376),the hypertension during the therapy(P=0.338)and hand-foot syndrome(P=0.201)were not independent risk factors affecting disease progression-free survival time of the advanced triple-negative patients.The treatment-related side effects were controlled and tolerated,were mild to moderate mostly and ranked as class 1 or 2.Conclusion Apatinib has a certain therapeutic effect on advanced triple-negative breast cancer and is worthy of further study.
作者
张伟杰
沈雪敬
李冬荟
王留兴
ZHANG Weijie;SHEN Xuejing;LI Donghui;WANG Liuxing(Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China)
出处
《肿瘤基础与临床》
2019年第4期283-287,共5页
journal of basic and clinical oncology
基金
河南省医学科技攻关项目(201602068)
关键词
晚期三阴性乳腺癌
阿帕替尼
临床疗效
安全性
血管内皮生长因子受体
advanced triple-negative breast cancer
apatinib
clinical efficacy
vascular endothelial growth factor receptor
